Home » Topics » BioWorld Science

BioWorld Science
RSS

Enrollment ongoing in phase I/II study of MB-102

Feb. 21, 2020

Mesoblast reports clinically meaningful outcomes for remestemcel-L in chronic GVHD

Feb. 21, 2020

Passengers, noncoding genome affect how cancers play out

Feb. 21, 2020

FDA approves IND application for phase IIb study of CMN-001 in advanced RCC

Feb. 21, 2020

JAK inhibitors build bone, no inflammation necessary

Feb. 21, 2020

New search method, new antibiotic MOA

Feb. 21, 2020

[68Ga]PSMA-11 PET/CT has a large effect on prostate cancer staging and management

Feb. 20, 2020

New phase I trial evaluates safety and immunogenicity of dengusiil

Feb. 20, 2020

Immutep reports interim data from phase II study of eftilagimod alpha in NSCLC and HNSCC

Feb. 20, 2020

GeneTX recruits pediatric patients with Angelman syndrome for phase I/II study of GTX-102

Feb. 20, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...